Dabrafenib 加曲美替尼在既往接受过治疗的局部晚期或转移性放射性碘难治性 BRAFV600E 突变阳性分化型甲状腺癌患者中的疗效和安全性研究
一项随机、双盲、安慰剂对照的 III 期研究,以评估 Dabrafenib 加曲美替尼在既往接受过治疗的局部晚期或转移性放射性碘难治性 BRAFV600E 突变阳性分化型甲状腺癌 (DTC) 患者中的疗效和安全性
The purpose of this study is to assess the efficacy and safety of dabrafenib in combination with trametinib for treating adult patients with locally advanced or metastatic Differentiated Thyroid Cancer (DTC) harboring the BRAFV600E mutation, who are refractory to radioactive iodine (RAI) therapy and have experienced disease progression following one or two prior VEGFR-targeted treatments.
研究概览
地位
详细说明
This is a global, multicenter, randomized, double-blind, placebo-controlled Phase III study designed to evaluate the efficacy and safety of dabrafenib plus trametinib in adult patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC) that is positive for the BRAF V600E mutation, refractory to radioactive iodine (RAI), and has progressed following prior vascular endothelial growth factor receptor (VEGFR) targeted therapy.
After eligibility assessment, patients will be randomized in a 2:1 ratio to receive either dabrafenib plus trametinib or placebo. Patients will be stratified by the number of prior VEGFR targeted therapies (one versus two) and prior lenvatinib treatment (yes versus no).
The scientific objective guiding the primary estimand is based on progression-free survival (PFS) as per blinded independent review committee (BIRC) assessment using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
This study will enroll approximately 150 patients.
Patients randomized to the placebo arm who experience disease progression as per RECIST 1.1 confirmed by BIRC and meet eligibility criteria will have the option to cross over to the open-label combination of dabrafenib plus trametinib.
Treatment may continue beyond RECIST 1.1 disease progression (confirmed by BIRC) if, in the investigator's judgment, there is evidence of clinical benefit and the patient wishes to remain on study treatment. In cases where there is a discrepancy between local site determination and BIRC (for example, disease progression determined locally but not by BIRC), the patient should not be discontinued from study treatment until progression is confirmed by BIRC or, at a minimum, until one additional tumor assessment has been completed, provided this is clinically acceptable.
After treatment discontinuation, all patients will be followed for safety and efficacy evaluations during the post-treatment follow-up period. Subsequently, patient status will be collected every 12 weeks as part of survival follow-up.
This study is ongoing, and enrollment was completed on 09-May-2024. The primary analysis was performed after all patients had either completed at least 16 weeks of treatment or discontinued early, and after approximately 95 PFS events had occurred.
研究类型
注册 (实际的)
阶段
- 第三阶段
联系人和位置
学习地点
-
-
-
Beijing、中国、100730
- Novartis Investigative Site
-
Beijing、中国、100036
- Novartis Investigative Site
-
Guangzhou、中国、510060
- Novartis Investigative Site
-
Shanghai、中国、200233
- Novartis Investigative Site
-
Tianjin、中国、300052
- Novartis Investigative Site
-
Tianjin、中国、300480
- Novartis Investigative Site
-
-
Fujian
-
Fuzhou、Fujian、中国、350014
- Novartis Investigative Site
-
-
Henan
-
Zhengzhou、Henan、中国、450008
- Novartis Investigative Site
-
-
Hubei
-
Wuhan、Hubei、中国、430022
- Novartis Investigative Site
-
-
Hunan
-
Changsha、Hunan、中国、410013
- Novartis Investigative Site
-
-
Jiangsu
-
Nanjing、Jiangsu、中国、210006
- Novartis Investigative Site
-
Nanjing、Jiangsu、中国、210009
- Novartis Investigative Site
-
Xuzhou、Jiangsu、中国、221003
- Novartis Investigative Site
-
-
Jilin
-
Changchun、Jilin、中国、130033
- Novartis Investigative Site
-
-
Sichuan
-
Chengdu、Sichuan、中国、610041
- Novartis Investigative Site
-
-
Tianjin Municipality
-
Tianjin、Tianjin Municipality、中国、300121
- Novartis Investigative Site
-
-
-
-
Alberta
-
Edmonton、Alberta、加拿大、T6G 1Z2
- Novartis Investigative Site
-
-
Ontario
-
London、Ontario、加拿大、N6A 5W9
- Novartis Investigative Site
-
-
-
-
-
Chennai、印度、600020
- Novartis Investigative Site
-
-
Haryana
-
Hisar、Haryana、印度、125005
- Novartis Investigative Site
-
-
National Capital Territory of Delhi
-
New Delhi、National Capital Territory of Delhi、印度、110029
- Novartis Investigative Site
-
-
-
-
-
Tainan、台湾、704302
- Novartis Investigative Site
-
Taipei、台湾、10002
- Novartis Investigative Site
-
-
-
-
Fatih
-
Istanbul、Fatih、土耳其(türkiye)、34098
- Novartis Investigative Site
-
-
Merkez
-
Edirne、Merkez、土耳其(türkiye)、22030
- Novartis Investigative Site
-
-
Yenimahalle
-
Ankara、Yenimahalle、土耳其(türkiye)、06500
- Novartis Investigative Site
-
-
Yuregir
-
Adana、Yuregir、土耳其(türkiye)、01250
- Novartis Investigative Site
-
-
-
-
Rio de Janeiro
-
Rio de Janiero、Rio de Janeiro、巴西、20231-050
- Novartis Investigative Site
-
-
Santa Catarina
-
Blumenau、Santa Catarina、巴西、89015-200
- Novartis Investigative Site
-
-
São Paulo
-
São Paulo、São Paulo、巴西、01246-000
- Novartis Investigative Site
-
-
-
-
Illinois
-
Chicago、Illinois、美国、60611
- Northwestern University Med School
-
-
Massachusetts
-
Boston、Massachusetts、美国、02114
- Massachusetts General Hospital
-
-
-
-
-
Hanoi、越南、100000
- Novartis Investigative Site
-
-
-
-
Buenos Aires
-
CABA、Buenos Aires、阿根廷、C1417DTB
- Novartis Investigative Site
-
-
-
-
-
Seoul、韩国、03080
- Novartis Investigative Site
-
Seoul、韩国、05505
- Novartis Investigative Site
-
Seoul、韩国、06351
- Novartis Investigative Site
-
Seoul、韩国、06591
- Novartis Investigative Site
-
-
-
-
-
Kuala Lumpur、马来西亚、59100
- Novartis Investigative Site
-
-
Pulau Pinang
-
George Town、Pulau Pinang、马来西亚、10450
- Novartis Investigative Site
-
-
Sarawak
-
Kuching、Sarawak、马来西亚、93586
- Novartis Investigative Site
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Key Inclusion Criteria:
- Signed informed consent
- Male or female ≥ 18 years of age at time of informed consent
- Histologically or cytologically confirmed diagnosis of advanced/metastatic differentiated thyroid carcinoma
- Radioactive-iodine refractory disease
- BRAF V600E mutation-positive tumor sample as per central laboratory result
- Has progressed on at least 1 but not more than 2 prior VEGFR targeted therapies
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
- At least one measurable lesion as defined by RECIST v1.1.
Key Exclusion Criteria:
- Anaplastic or medullary carcinoma of the thyroid
- Previous treatment with a BRAF inhibitor and/or a MEK inhibitor
- Concomitant RET Fusion-Positive Thyroid Cancer
- Treatment with any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks before randomization
- Treatment with any type of anticancer antibody (including investigational antibody) or systemic chemotherapy within 4 weeks before randomization
- Treatment with radiation therapy for bone metastasis within 2 weeks or any other radiation therapy within 4 weeks before randomization
- A history or current evidence/risk of retinal vein occlusion (RVO) or central serous retinopathy
Other inclusion/exclusion criteria may apply.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:交叉作业
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Dabrafenib plus Trametinib
Eligible participants will receive Dabrafenib 150 mg twice a day (BID) and Trametinib 2 mg once a day (QD) until disease progression as per RECIST 1.1 as confirmed by blinded independent review committee (BIRC), unacceptable toxicity, pregnancy, loss of clinical benefit as determined by the investigator, withdrawal of consent, lost to follow-up, death, or study termination by the sponsor. |
Dabrafenib 150 mg capsule administered orally twice a day (BID)
其他名称:
Trametinib 2 mg tablet administered once a day (QD)
其他名称:
|
|
安慰剂比较:Dabrafenib Placebo plus Trametinib Placebo
Eligible participants will receive matching placebo for Dabrafenib 150 mg twice a day (BID) and matching placebo for Trametinib 2 mg once a day (QD) until disease progression as per RECIST 1.1 as confirmed by blinded independent review committee (BIRC), unacceptable toxicity, pregnancy, loss of clinical benefit as determined by the investigator, withdrawal of consent, lost to follow-up, death, or study termination by the sponsor. |
matching placebo tablet for Trametinib 2 mg will be administered orally once a day (QD) matching placebo capsule for Dabrafenib 150 mg will be administered orally twice a day (BID) |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Progression Free Survival (PFS)
大体时间:From randomization to first documented progression or deaths, whichever comes first, assessed up to approximately 3 years
|
Progression Free Survival (PFS) was defined as the time from the date of randomization to the date of the first documented progression according to RECIST 1.1 based on Blinded Independent Review Committee (BIRC) assessment, or death due to any cause. The primary analysis was conducted after all patients had either completed a minimum of 16 weeks of treatment or discontinued earlier, and following the occurrence of approximately 95 PFS events (Data cut-off date for the primary analysis was 22 January 2025). |
From randomization to first documented progression or deaths, whichever comes first, assessed up to approximately 3 years
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Overall Response Rate (ORR)
大体时间:From randomization assessed through Primary Analysis Cut-off date (approximately 3 years)
|
Overall Response Rate (ORR) was defined as the proportion of participants who had a Best Overall Response (BOR) of confirmed Complete Response (CR) or Partial Response (PR) according to RECIST 1.1. |
From randomization assessed through Primary Analysis Cut-off date (approximately 3 years)
|
|
Overall Survival (OS)
大体时间:From randomization to death assessed up to approximately 5 years
|
Overall Survival (OS) is defined as the time from the date of randomization to the date of death due to any cause. |
From randomization to death assessed up to approximately 5 years
|
|
Duration of Response (DOR)
大体时间:From the first documented complete or partial response to the first documented progression or death, assessed up to Primary Analysis Cut-off date (approximately 3 years)
|
Duration of Response (DOR) applied only to patients whose Best Overall Response (BOR) was a confirmed Complete Response (CR) or Partial Response (PR) according to RECIST 1.1. The start date was defined as the date of the first documented confirmed CR or PR, and the end date corresponded to the date of the first documented confirmed progression or death from any cause. Patients who remained without progression or death from any cause were censored at the date of their last adequate tumor assessment prior to the initiation of any new antineoplastic therapy. |
From the first documented complete or partial response to the first documented progression or death, assessed up to Primary Analysis Cut-off date (approximately 3 years)
|
|
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
大体时间:Throughout study completion, an average 5 years
|
The distribution of adverse events will be conducted through the analysis of frequencies for treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs), based on the monitoring of relevant clinical and laboratory safety parameters. Treatment-emergent adverse events (TEAEs) in this study will be defined as events that begin after the first dose of study treatment and continue until 30 days after the last dose, or events that are present prior to the first dose and increase in severity based on preferred term within 30 days following the last dose. |
Throughout study completion, an average 5 years
|
|
Number of Participants With Trametinib Associated Serous Retinopathy Ocular Events
大体时间:Up to approximately 3 years
|
Analysis of the optical coherence tomography data was performed to assess the incidence, type, and severity of trametinib-associated serous retinopathy ocular events, using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 grading system: Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (life-threatening), and Grade 5 (death related to adverse event). |
Up to approximately 3 years
|
合作者和调查者
调查人员
- 研究主任:Novartis Pharmaceuticals、Novartis Pharmaceuticals
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他相关的 MeSH 术语
其他研究编号
- CDRB436J12301
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.